Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2011

Open Access 01-12-2011 | Primary research

An inhibitor of K+ channels modulates human endometrial tumor-initiating cells

Authors: Brandon M Schickling, Nukhet Aykin-Burns, Kimberly K Leslie, Douglas R Spitz, Victoria P Korovkina

Published in: Cancer Cell International | Issue 1/2011

Login to get access

Abstract

Background

Many potassium ion (K+) channels function as oncogenes to sustain growth of solid tumors, but their role in cancer progression is not well understood. Emerging evidence suggests that the early progenitor cancer cell subpopulation, termed tumor initiating cells (TIC), are critical to cancer progression.

Results

A non-selective antagonist of multiple types of K+ channels, tetraethylammonium (TEA), was found to suppress colony formation in endometrial cancer cells via inhibition of putative TIC. The data also indicated that withdrawal of TEA results in a significant enhancement of tumorigenesis. When the TIC-enriched subpopulation was isolated from the endometrial cancer cells, TEA was also found to inhibit growth in vitro.

Conclusions

These studies suggest that the activity of potassium channels significantly contributes to the progression of endometrial tumors, and the antagonists of potassium channels are candidate anti-cancer drugs to specifically target tumor initiating cells in endometrial cancer therapy.
Appendix
Available only for authorised users
Literature
1.
Stuhmer W, Pardo LA: K(+) channels as therapeutic targets in oncology. Future Med Chem. 2010, 2: 745-755. 10.4155/fmc.10.24.CrossRefPubMed
2.
Asher V, Sowter H, Shaw R, Bali A, Khan R: Eag and HERG potassium channels as novel therapeutic targets in cancer. World J Surg Oncol. 2010, 8: 113-10.1186/1477-7819-8-113.PubMedCentralCrossRefPubMed
3.
Ernest NJ, Logsdon NJ, McFerrin MB, Sontheimer H, Spiller SE: Biophysical properties of human medulloblastoma cells. J Membr Biol. 2010, 237: 59-69. 10.1007/s00232-010-9306-x.CrossRefPubMed
4.
Bielanska J, Hernandez-Losa J, Perez-Verdaguer M, Moline T, Somoza R, Ramon YCS, Condom E, Ferreres JC, Felipe A: Voltage-dependent potassium channels Kv1.3 and Kv1.5 in human cancer. Curr Cancer Drug Targets. 2009, 9: 904-914. 10.2174/156800909790192400.CrossRefPubMed
5.
Wondergem R, Bartley JW: Menthol increases human glioblastoma intracellular Ca2+, BK channel activity and cell migration. J Biomed Sci. 2009, 16: 90-10.1186/1423-0127-16-90.PubMedCentralCrossRefPubMed
6.
Khaitan D, Sankpal UT, Weksler B, Meister EA, Romero IA, Couraud PO, Ningaraj NS: Role of KCNMA1 gene in breast cancer invasion and metastasis to brain. BMC Cancer. 2009, 9: 258-10.1186/1471-2407-9-258.PubMedCentralCrossRefPubMed
7.
Brevet M, Haren N, Sevestre H, Merviel P, Ouadid-Ahidouch H: DNA methylation of K(v)1.3 potassium channel gene promoter is associated with poorly differentiated breast adenocarcinoma. Cell Physiol Biochem. 2009, 24: 25-32. 10.1159/000227810.CrossRefPubMed
8.
Nakamura M, Kyo S, Zhang B, Zhang X, Mizumoto Y, Takakura M, Maida Y, Mori N, Hashimoto M, Ohno S, Inoue M: Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. Hum Pathol. 2010, 41: 1516-1529. 10.1016/j.humpath.2010.05.006.CrossRefPubMed
9.
Chantome A, Girault A, Potier M, Collin C, Vaudin P, Pages JC, Vandier C, Joulin V: KCa2.3 channel-dependent hyperpolarization increases melanoma cell motility. Exp Cell Res. 2009, 315: 3620-3630. 10.1016/j.yexcr.2009.07.021.CrossRefPubMed
10.
Blackiston DJ, McLaughlin KA, Levin M: Bioelectric controls of cell proliferation: ion channels, membrane voltage and the cell cycle. Cell Cycle. 2009, 8: 3519-3528.PubMedCentralCrossRef
11.
Sciaccaluga M, Fioretti B, Catacuzzeno L, Pagani F, Bertollini C, Rosito M, Catalano M, D'Alessandro G, Santoro A, Cantore G, Ragozzino D, Castigli E, Franciolini F, Limatola C: CXCL12-induced glioblastoma cell migration requires intermediate conductance Ca2+-activated K+ channel activity. Am J Physiol Cell Physiol. 2010, 299: C175-184. 10.1152/ajpcell.00344.2009.CrossRefPubMed
12.
Becchetti A, Arcangeli A: Integrins and ion channels in cell migration: implications for neuronal development, wound healing and metastatic spread. Adv Exp Med Biol. 2010, 674: 107-123. 10.1007/978-1-4419-6066-5_10.CrossRefPubMed
13.
Haren N, Khorsi H, Faouzi M, Ahidouch A, Sevestre H, Ouadid-Ahidouch H: Intermediate conductance Ca2+ activated K+ channels are expressed and functional in breast adenocarcinomas: correlation with tumour grade and metastasis status. Histol Histopathol. 2010, 25: 1247-1255.PubMed
14.
Lee I, Park C, Kang WK: Knockdown of inwardly rectifying potassium channel Kir2.2 suppresses tumorigenesis by inducing reactive oxygen species-mediated cellular senescence. Mol Cancer Ther. 2010, 9: 2951-2959. 10.1158/1535-7163.MCT-10-0511.CrossRefPubMed
15.
Fortunato P, Pillozzi S, Tamburini A, Pollazzi L, Franchi A, La Torre A, Arcangeli A: Irresponsiveness of two retinoblastoma cases to conservative therapy correlates with up- regulation of hERG1 channels and of the VEGF-A pathway. BMC Cancer. 2010, 10: 504-10.1186/1471-2407-10-504.PubMedCentralCrossRefPubMed
16.
Tajima N, Itokazu Y, Korpi ER, Somerharju P, Kakela R: Activity of BK(Ca) channel is modulated by membrane cholesterol content and association with Na+/K+-ATPase in human melanoma IGR39 cells. J Biol Chem. 2011, 286: 5624-5638. 10.1074/jbc.M110.149898.PubMedCentralCrossRefPubMed
17.
Asher V, Khan R, Warren A, Shaw R, Schalkwyk GV, Bali A, Sowter HM: The Eag potassium channel as a new prognostic marker in ovarian cancer. Diagn Pathol. 2010, 5: 78-10.1186/1746-1596-5-78.PubMedCentralCrossRefPubMed
18.
Jelassi B, Chantome A, Alcaraz-Perez F, Baroja-Mazo A, Cayuela ML, Pelegrin P, Surprenant A, Roger S: P2X(7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness. Oncogene. 2011, 30: 2108-2122. 10.1038/onc.2010.593.CrossRefPubMed
19.
Lallet-Daher H, Roudbaraki M, Bavencoffe A, Mariot P, Gackiere F, Bidaux G, Urbain R, Gosset P, Delcourt P, Fleurisse L, Slomianny C, Dewailly E, Mauroy B, Bonnal JL, Skryma R, Prevarskaya N: Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry. Oncogene. 2009, 28: 1792-1806. 10.1038/onc.2009.25.CrossRefPubMed
20.
Asher V, Warren A, Shaw R, Sowter H, Bali A, Khan R: The role of Eag and HERG channels in cell proliferation and apoptotic cell death in SK-OV-3 ovarian cancer cell line. Cancer Cell Int. 2011, 11: 6-10.1186/1475-2867-11-6.PubMedCentralCrossRefPubMed
21.
Kim HJ, Jang SH, Jeong YA, Ryu PD, Kim DY, Lee SY: Involvement of Kv4.1 K(+) channels in gastric cancer cell proliferation. Biol Pharm Bull. 2010, 33: 1754-1757. 10.1248/bpb.33.1754.CrossRefPubMed
22.
Biderman B, Marakhonov A, Skoblov M, Birerdinc A, Nohelty E, Page S, Khomenkov V, Chandhoke V, Sudarikov A, Nikitin E, Baranova A: Inhibition of potassium currents as a pharmacologic target for investigation in chronic lymphocytic leukemia. Drug News Perspect. 2010, 23: 625-631. 10.1358/dnp.2010.23.10.1507740.CrossRefPubMed
23.
Pillozzi S, Masselli M, De Lorenzo E, Accordi B, Cilia E, Crociani O, Amedei A, Veltroni M, D'Amico M, Basso G, Becchetti A, Campana D, Arcangeli A: Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood. 2011, 117: 902-914. 10.1182/blood-2010-01-262691.CrossRefPubMed
24.
Agarwal JR, Griesinger F, Stuhmer W, Pardo LA: The potassium channel Ether a go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia. Mol Cancer. 2010, 9: 18-10.1186/1476-4598-9-18.PubMedCentralCrossRefPubMed
25.
Jang SH, Kang KS, Ryu PD, Lee SY: Kv1.3 voltage-gated K(+) channel subunit as a potential diagnostic marker and therapeutic target for breast cancer. BMB Rep. 2009, 42: 535-539. 10.5483/BMBRep.2009.42.8.535.CrossRefPubMed
26.
Dolderer JH, Schuldes H, Bockhorn H, Altmannsberger M, Lambers C, von Zabern D, Jonas D, Schwegler H, Linke R, Schroder UH: HERG1 gene expression as a specific tumor marker in colorectal tissues. Eur J Surg Oncol. 2010, 36: 72-77.CrossRefPubMed
27.
Teng IW, Hou PC, Lee KD, Chu PY, Yeh KT, Jin VX, Tseng MJ, Tsai SJ, Chang YSD, Wu CS, Sun HS, Tsai KD, Jeng LB, Nephew KP, Huang TH, Hsiao SH, Leu YW: Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells. Cancer Res. 2011
28.
Kano M, Tsukahara T, Emori M, Murase M, Torigoe T, Kawaguchi S, Wada T, Yamashita T, Sato N: Autologous CTL response against cancer stem-like cells/cancer-initiating cells of bone malignant fibrous histiocytoma. Cancer Sci. 2011
29.
Deleyrolle LP, Harding A, Cato K, Siebzehnrubl FA, Rahman M, Azari H, Olson S, Gabrielli B, Osborne G, Vescovi A, Reynolds BA: Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain. 2011, 134: 1331-1343. 10.1093/brain/awr081.PubMedCentralCrossRefPubMed
30.
Albitar L, Pickett G, Morgan M, Davies S, Leslie KK: Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells. Gynecol Oncol. 2007, 106: 52-64. 10.1016/j.ygyno.2007.02.033.CrossRefPubMed
31.
Cherubini A, Taddei GL, Crociani O, Paglierani M, Buccoliero AM, Fontana L, Noci I, Borri P, Borrani E, Giachi M, Becchetti A, Rosati B, Wanke E, Olivotto M, Arcangeli A: HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium. Br J Cancer. 2000, 83: 1722-1729. 10.1054/bjoc.2000.1497.PubMedCentralCrossRefPubMed
32.
Wang ZH, Shen B, Yao HL, Jia YC, Ren J, Feng YJ, Wang YZ: Blockage of intermediate-conductance-Ca(2+) -activated K(+) channels inhibits progression of human endometrial cancer. Oncogene. 2007, 26: 5107-5114. 10.1038/sj.onc.1210308.CrossRefPubMed
33.
Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP: Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell. 2010, 140: 62-73. 10.1016/j.cell.2009.12.007.CrossRefPubMed
34.
Heerma van Voss MR, van der Groep P, Bart J, van der Wall E, van Diest PJ: Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer. Cell Oncol (Dordr). 2011, 34: 3-10.CrossRef
35.
Rahadiani N, Ikeda J, Mamat S, Matsuzaki S, Ueda Y, Umehara R, Tian T, Wang Y, Enomoto T, Kimura T, Aozasa K, Morii E: Expression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications. Cancer Sci. 2011, 102: 903-908. 10.1111/j.1349-7006.2011.01864.x.CrossRefPubMed
36.
Kusumbe AP, Bapat SA: Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res. 2009, 69: 9245-9253. 10.1158/0008-5472.CAN-09-2802.CrossRefPubMed
37.
Potier M, Chantome A, Joulin V, Girault A, Roger S, Besson P, Jourdan ML, LeGuennec JY, Bougnoux P, Vandier C: The SK3/K(Ca)2.3 potassium channel is a new cellular target for edelfosine. Br J Pharmacol. 2011, 162: 464-479. 10.1111/j.1476-5381.2010.01044.x.PubMedCentralCrossRefPubMed
Metadata
Title
An inhibitor of K+ channels modulates human endometrial tumor-initiating cells
Authors
Brandon M Schickling
Nukhet Aykin-Burns
Kimberly K Leslie
Douglas R Spitz
Victoria P Korovkina
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2011
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-11-25

Other articles of this Issue 1/2011

Cancer Cell International 1/2011 Go to the issue

Primary research

Co-cultivation of murine BMDCs with 67NR mouse mammary carcinoma cells give rise to highly drug resistant cells

Review

Therapeutics formulated to target cancer stem cells: Is it in our future?

Primary research

In vitro effects of 2-methoxyestradiol-bis-sulphamate on reactive oxygen species and possible apoptosis induction in a breast adenocarcinoma cell line

Primary research

MHC class I-related chain A and B ligands are differentially expressed in human cervical cancer cell lines

Primary research

Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition

Erratum

Erratum to: ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits